知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.02 秒)

    Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen
    1.
    发明授权
    Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen 有权
    包含单核细胞或未成熟骨髓细胞（IMC）的疫苗，其装载有天然杀伤T细胞和抗原的配体

    公开(公告)号：US09518126B2

    公开(公告)日：2016-12-13

    申请号：US12279166

    申请日：2007-11-28

    申请人： Chang-Yuil Kang ,  Hyun-Jeong Ko ,  Jung-Mi Lee ,  Yeon-Jeong Kim

    发明人： Chang-Yuil Kang ,  Hyun-Jeong Ko ,  Jung-Mi Lee ,  Yeon-Jeong Kim

    IPC分类号： A61K31/164 ,  C12N5/0786 ,  A61K39/00 ,  C07K16/32

    CPC分类号： C07K16/32 ,  A61K31/164 ,  A61K39/00 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N5/0645 ,  C12N2501/999 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472 ,  Y02A50/476

    摘要： The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.

    摘要翻译： 本发明涉及包含负载天然杀伤T细胞配体的单核细胞或未成熟骨髓细胞（IMC）的免疫治疗和预防性疫苗，以及用于预防和治疗感染性疾病或癌症的抗原，更准确地说， 包含装载有α-半乳糖神经酰胺（αGalCer），一种糖脂和天然杀伤T细胞配体的单核细胞或IMC的治疗和预防性疫苗和抗原。 与树突状细胞不同，易于获得的单核细胞或未成熟骨髓细胞（IMC）不仅诱导显着水平的细胞毒性T淋巴细胞应答，而且对恶性肿瘤具有预防和治疗作用。 因此，本发明的免疫治疗和预防性疫苗可以有效地用作免疫治疗剂。

    B cell-based vaccine loaded with the ligand of natural killer T cell and antigen
    2.
    发明授权
    B cell-based vaccine loaded with the ligand of natural killer T cell and antigen 有权
    以B细胞为基础的疫苗，加载有天然杀伤T细胞和抗原的配体

    公开(公告)号：US08003093B2

    公开(公告)日：2011-08-23

    申请号：US11718391

    申请日：2006-04-27

    申请人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    发明人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    IPC分类号： A01N63/02 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/5156 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472

    摘要： The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

    摘要翻译： 本发明涉及一种负载有天然杀伤T细胞配体的B细胞疫苗和用于预防和治疗疾病的抗原，更具体地说，涉及一种由装载有α-半乳糖神经酰胺的B细胞介导的免疫治疗和预防性疫苗 的可以刺激天然杀伤T细胞的糖脂。 本发明的疫苗组合物可以有效地用作抗肿瘤免疫治疗剂。 B细胞与树突细胞相比容易获得，不仅诱导与常规树突状细胞基疫苗相似的细胞毒性T淋巴细胞水平的水平，而且对实体瘤和转移性肿瘤具有预防和治疗作用。

    ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY
    6.
    发明申请
    ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY 审中-公开
    包含抗PD-1抗体或抗PD-L1抗体的抗体试剂

    公开(公告)号：US20100086550A1

    公开(公告)日：2010-04-08

    申请号：US12410732

    申请日：2009-03-25

    申请人： Chang Yuil Kang ,  Woo Sung Chang ,  Ji Yeon Kim

    发明人： Chang Yuil Kang ,  Woo Sung Chang ,  Ji Yeon Kim

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2818 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2300/00

    摘要： Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

    摘要翻译： 提供一种抗癌剂，其包含抗PD-1抗体或抗-PD-L1抗体作为活性成分，其功能是通过用iNKT细胞配体施用而逆转已经诱导了无反应性的iNKT细胞的无反应性。 抗PD-1或抗PD-L1抗体阻断PD-1 / PD-L1介导的信号通路，不仅可以防止iNKT细胞配体诱导的iNKT细胞无反应，而且可以逆转已经无能的iNKT的无反应性 细胞产生细胞因子。 此外，抗PD1或抗PD-L1抗体确保iNKT细胞的有效的抗肿瘤活性，如通过体内B16F10黑素瘤转移模型中转移性结节数量的显着减少所证实的。 总的来说，抗癌剂在治疗癌症，特别是转移性癌症中是非常有用的。

    B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN
    7.
    发明申请
    B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN 有权
    基于B细胞的疫苗与天然杀伤细胞和抗原的配体

    公开(公告)号：US20100028380A1

    公开(公告)日：2010-02-04

    申请号：US11718391

    申请日：2006-04-27

    申请人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    发明人： Chang-Yuil Kang ,  Yeonseok Chung ,  Hyun-Jeong Ko ,  Yeon-Jeong Kim ,  Byung-Seok Kim ,  Sung-Youl Ko

    IPC分类号： A61K39/12 ,  A61K39/00 ,  A61K39/02

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K2039/5156 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/472

    摘要： The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

    摘要翻译： 本发明涉及一种装载有天然杀伤T细胞配体的B细胞疫苗和用于预防和治疗疾病的抗原，更具体地说，涉及一种由装载有α-半乳糖神经酰胺的B细胞介导的免疫治疗和预防性疫苗 的可以刺激天然杀伤T细胞的糖脂。 本发明的疫苗组合物可以有效地用作抗肿瘤免疫治疗剂。 B细胞与树突细胞相比容易获得，不仅诱导与常规树突状细胞基疫苗相似的细胞毒性T淋巴细胞水平的水平，而且对实体瘤和转移性肿瘤具有预防和治疗作用。

    Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody
    8.
    发明授权
    Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody 有权
    包含抗PD-1抗体或抗-PD-L1抗体的抗癌剂

    公开(公告)号：US08617546B2

    公开(公告)日：2013-12-31

    申请号：US13398915

    申请日：2012-02-17

    申请人： Chang Yuil Kang ,  Woo Sung Chang ,  Ji Yeon Kim ,  Dong-Hyeon Kim

    发明人： Chang Yuil Kang ,  Woo Sung Chang ,  Ji Yeon Kim ,  Dong-Hyeon Kim

    IPC分类号： A61K39/00

    CPC分类号： C07K16/2818 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2300/00

    摘要： Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

    摘要翻译： 提供一种抗癌剂，其包含抗PD-1抗体或抗-PD-L1抗体作为活性成分，其功能是通过用iNKT细胞配体施用而逆转已经诱导了无反应性的iNKT细胞的无反应性。 抗PD-1或抗PD-L1抗体阻断PD-1 / PD-L1介导的信号通路，不仅可以防止iNKT细胞配体诱导的iNKT细胞无反应，而且可以逆转已经无能的iNKT的无反应性 细胞产生细胞因子。 此外，抗PD1或抗PD-L1抗体确保iNKT细胞的有效的抗肿瘤活性，如通过体内B16F10黑素瘤转移模型中转移性结节数量的显着减少所证实的。 总的来说，抗癌剂在治疗癌症，特别是转移性癌症中是非常有用的。

    ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY
    9.
    发明申请
    ANTICANCER AGENT COMPRISING ANTI-PD-1 ANTIBODY OR ANTI-PD-L1 ANTIBODY 有权
    包含抗PD-1抗体或抗PD-L1抗体的抗体试剂

    公开(公告)号：US20120237522A1

    公开(公告)日：2012-09-20

    申请号：US13398915

    申请日：2012-02-17

    申请人： Chang Yuil KANG ,  Woo Sung CHANG ,  Ji Yeon KIM ,  Dong-Hyeon KIM

    发明人： Chang Yuil KANG ,  Woo Sung CHANG ,  Ji Yeon KIM ,  Dong-Hyeon KIM

    IPC分类号： A61K39/395 ,  A61P35/02 ,  A61P35/00

    CPC分类号： C07K16/2818 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2827 ,  C07K2317/76 ,  A61K2300/00

    摘要： Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not only to prevent the iNKT cell ligand-induced iNKT cell anergy, but also to reverse the unresponsiveness of already anergic iNKT cells to produce cytokines. In addition, the anti-PD1 or anti-PD-L1 antibody ensures the potent anti-tumor activity of iNKT cells as demonstrated by a significant reduction in the number of metastatic nodules in B16F10 melanoma metastasis models in vivo. Collectively, the anticancer agent can be very useful in the treatment of cancer, particularly metastatic cancer.

    摘要翻译： 提供一种抗癌剂，其包含抗PD-1抗体或抗-PD-L1抗体作为活性成分，其功能是通过用iNKT细胞配体施用而逆转已经诱导了无能力的iNKT细胞的无反应性。 抗PD-1或抗PD-L1抗体阻断PD-1 / PD-L1介导的信号通路，不仅可以防止iNKT细胞配体诱导的iNKT细胞无反应，而且可以逆转已经无能的iNKT的无反应性 细胞产生细胞因子。 此外，抗PD1或抗PD-L1抗体确保iNKT细胞的有效的抗肿瘤活性，如通过体内B16F10黑素瘤转移模型中转移性结节数量的显着减少所证实的。 总的来说，抗癌剂在治疗癌症，特别是转移性癌症中是非常有用的。

    Humanized antibody specific for human 4-1BB
    10.
    发明授权
    Humanized antibody specific for human 4-1BB 失效
    对人4-1BB特异的人源化抗体

    公开(公告)号：US06458934B1

    公开(公告)日：2002-10-01

    申请号：US09438954

    申请日：1999-11-12

    申请人： Hyo Jeong Hong ,  Sung Sup Park ,  Young Jun Kang ,  Chang-Yuil Kang ,  Sung Kwan Yoon

    发明人： Hyo Jeong Hong ,  Sung Sup Park ,  Young Jun Kang ,  Chang-Yuil Kang ,  Sung Kwan Yoon

    IPC分类号： C07K1618

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2319/00

    摘要： The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.

    摘要翻译： 本发明涉及特异性结合蛋白4-1BB的人源化抗体。 可以通过将小鼠单克隆抗体的互补决定区（CDR）与人4-1BB接枝到人抗体的其余部分并进一步进行氨基酸替换来制备抗体。 此外，可以制备包含人源化抗体的药物组合物，并且可以用于治疗自身免疫疾病以抑制免疫应答。 本发明的人源化抗体对人4-1BB具有高亲和力，与人抗体具有序列相似性。 结果，本发明的药物组合物可以用于治疗自身免疫性疾病，并且在人体中作为免疫抑制剂没有太多的副作用。